Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Eron

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
AIDS Patient Care and Stds|June 6, 2014
Total daily pill burden in HIV-infected patients in the southern United StatesShuntai Zhou, Kelly Martin, Amanda Corbett, et al.
Open Forum Infectious Diseases|August 21, 2023
Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence BarriersWanyi Chen, Monica Gandhi, Paul E Sax, et al.
Lancet (London, England)|August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialJoseph Eron, Patrick Yeni, Joseph Gathe, et al.
Plos One|November 15, 2014
HIV cure strategies: how good must they be to improve on current antiretroviral therapy?Paul E Sax, Alexis Sypek, Bethany K Berkowitz, et al.
The Lancet. Microbe|February 20, 2026
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 studyOnyema Ogbuagu, Aditya Gaur, James H McMahon, et al.
The Journal of Clinical Investigation|July 18, 2017
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latencyNancie M Archin, Jennifer L Kirchherr, Julia Am Sung, et al.
The Journal of Infectious Diseases|June 7, 2023
Use of Next-Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-COV-2 Pandemic on HIV-1 Diagnosis and TransmissionShuntai Zhou, Nathan Long, Matt Moeser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2007
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatmentAlan Landay, Barbara A da Silva, Martin S King, et al.
The Journal of Infectious Diseases|July 15, 2020
Near Real-Time Identification of Recent Human Immunodeficiency Virus Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by Multiplexed Primer ID-Next-Generation Sequencing in North CarolinaShuntai Zhou, Sabrina Sizemore, Matt Moeser, et al.
AIDS (London, England)|March 20, 2024
Incidence of non-AIDS defining comorbidities among young adults with perinatally acquired HIV in North AmericaNel Jason L Haw, Catherine R Lesko, Derek K Ng, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
AIDS Patient Care and Stds|June 6, 2014
Total daily pill burden in HIV-infected patients in the southern United StatesShuntai Zhou, Kelly Martin, Amanda Corbett, et al.
Open Forum Infectious Diseases|August 21, 2023
Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence BarriersWanyi Chen, Monica Gandhi, Paul E Sax, et al.
Lancet (London, England)|August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialJoseph Eron, Patrick Yeni, Joseph Gathe, et al.
Plos One|November 15, 2014
HIV cure strategies: how good must they be to improve on current antiretroviral therapy?Paul E Sax, Alexis Sypek, Bethany K Berkowitz, et al.
The Lancet. Microbe|February 20, 2026
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 studyOnyema Ogbuagu, Aditya Gaur, James H McMahon, et al.
The Journal of Clinical Investigation|July 18, 2017
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latencyNancie M Archin, Jennifer L Kirchherr, Julia Am Sung, et al.
The Journal of Infectious Diseases|June 7, 2023
Use of Next-Generation Sequencing in a State-Wide Strategy of HIV-1 Surveillance: Impact of the SARS-COV-2 Pandemic on HIV-1 Diagnosis and TransmissionShuntai Zhou, Nathan Long, Matt Moeser, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2007
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatmentAlan Landay, Barbara A da Silva, Martin S King, et al.
The Journal of Infectious Diseases|July 15, 2020
Near Real-Time Identification of Recent Human Immunodeficiency Virus Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by Multiplexed Primer ID-Next-Generation Sequencing in North CarolinaShuntai Zhou, Sabrina Sizemore, Matt Moeser, et al.
AIDS (London, England)|March 20, 2024
Incidence of non-AIDS defining comorbidities among young adults with perinatally acquired HIV in North AmericaNel Jason L Haw, Catherine R Lesko, Derek K Ng, et al.
Pageof 7